Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
10/2003
10/15/2003CN1124276C Rapamycin derivatives
10/15/2003CN1124262C Indole derivatives useful as endothelin receptor antagonists
10/14/2003US6632963 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
10/14/2003US6632945 Treating inflammation, autoimmune diseases, destructive bone disorders, proliferative disorders, infections, neurvous system disorders, reperfusion/ischemia in stroke, cardiovascular disorders, hypoxia, edema, fever, pain
10/14/2003US6632926 Amino acids inserted in hypervariable region; heavy chain variable domain of an antibody that binds vascular endothelial growth factor
10/14/2003US6632920 Immunology; diagnosing cancer, nervous system, brain, sleep, psychological, and disorders
10/14/2003US6632842 Reducing medication error and enhancing therapeutic compliance of an individual suffering from COPD by providing a single use inhaler
10/14/2003US6632836 To treat autoimmune disorders, cardiac arrhythmias and the like
10/14/2003US6632830 ACE-2 inhibiting compounds and methods of use thereof
10/14/2003US6632829 Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases
10/14/2003US6632814 Dihydro-benzo(1,4)oxazines
10/14/2003US6632810 Cyclic diamine compound with condensed-ring groups
10/14/2003US6632440 Chronic obstructive pulmonary disease (COPD), asthma; Aerosol administration a compound that inhibits exocytosis in mucus secreting cells produced by modifying a clostridial neurotoxin
10/14/2003CA2385777A1 Use of anti-tnf.alpha.antibodies and another drug
10/14/2003CA2082740C Controlled release device
10/09/2003WO2003083135A2 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
10/09/2003WO2003083092A1 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
10/09/2003WO2003083039A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/09/2003WO2003082893A2 Theraputic methods and uses of sapogenins and their derivatives
10/09/2003WO2003082873A1 New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives
10/09/2003WO2003082872A1 Novel pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
10/09/2003WO2003082871A1 Imidazo fused compounds
10/09/2003WO2003082868A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
10/09/2003WO2003082867A1 Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
10/09/2003WO2003082863A1 N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases
10/09/2003WO2003082862A1 Anti-inflammatory morpholin-acetamide derivatives
10/09/2003WO2003082861A2 Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
10/09/2003WO2003082839A1 (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
10/09/2003WO2003082829A1 New aryl imidazoles and related compounds as c5a receptor modulators
10/09/2003WO2003082827A1 Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents
10/09/2003WO2003082813A2 Improvements in pharmaceutical compositions
10/09/2003WO2003082808A1 Benzamide derivatives
10/09/2003WO2003082787A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/09/2003WO2003082359A1 Tissue treatment
10/09/2003WO2003082349A1 Treatment methods for eotaxin mediated inflammatory conditions
10/09/2003WO2003082322A1 A method of modulating cellular activity
10/09/2003WO2003082320A1 Novel screening method
10/09/2003WO2003082314A2 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
10/09/2003WO2003082295A1 Morpholine derivatives substituted at the 2-position by a heterocyclylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions
10/09/2003WO2003082294A1 Morpholine derivatives with a substituted acetamide group in the 2-position for use as ccr-3 antagonists for the treatment of inflammatory diseases
10/09/2003WO2003082293A1 Benzenesulphonate salt of a morpholine urea derivative for use as a ccr-3 antagonist in the treatment of inflammatory conditions
10/09/2003WO2003082292A1 Morpholine derivatives substituted at the 2-position by an arylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions
10/09/2003WO2003082291A1 N-{´ (2s) -4- (3, 4-difluorobenzyl) morpholin-2yl!methyl} -2-{3-' (methylsulphonyl) amino! phenyl}acetamide as ccr3 antagonist for the treatment of inflammatory conditions
10/09/2003WO2003082290A1 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
10/09/2003WO2003082285A1 Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
10/09/2003WO2003082282A1 Method of use
10/09/2003WO2003082277A1 Thiazol-2-yl-imine compounds as pde-7 inhibitors
10/09/2003WO2003082268A2 Hemiasterlin derivatives and uses thereof in the treatment of cancer
10/09/2003WO2003082264A1 Pharmaceutical composition for preventing or treating respiratory disease
10/09/2003WO2003082253A1 A method for treating carrier particles and its use
10/09/2003WO2003082252A1 Hfa-suspension formulations containing an anticholinergic
10/09/2003WO2003082244A2 Hfa-suspension formulation of an anhydrate
10/09/2003WO2003082191A2 Substituted 2,3-diphenyl pyridines
10/09/2003WO2003082190A2 Spirocyclic amides as cannabinoid receptor modulators
10/09/2003WO2003045917A3 Ccr-3 receptor antagonists vii
10/09/2003WO2003037367A3 New bacterium causing poultry disease and vaccine derived thereof
10/09/2003WO2003028626A3 Glucagon-like peptides (glp-1) and treatment of respiratory distress
10/09/2003WO2003016528A3 Oligonucleotide compositions and their use to induce apoptosis
10/09/2003WO2003013534A3 Methods for the treatment of cancer with irinotecan based on cyp3a5
10/09/2003WO2003013533A3 Methods for improved treatment of cancer with irinotecan based on mrp1
10/09/2003WO2002092004A3 Use of hmg fragment as anti-inflammatory agents
10/09/2003WO2002083627A3 Ligands des integrins avss6
10/09/2003WO2002078747A3 Pregabalin lactose conjugates
10/09/2003WO2002078682A3 Estrogen replacement therapy
10/09/2003WO2002077017A3 Medical uses of intercellular communication facilitating compounds
10/09/2003WO2002069905A3 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
10/09/2003WO2002055063A3 Fumaric acid amides
10/09/2003WO2002033099A3 Human kinases
10/09/2003WO2002026245A3 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
10/09/2003US20030191316 A 2-fluorocycloalkyl-2-hydroxy-2-phenyl-ethanoyl)oxy amine salt derivatives; antagonist for treating diseases associated with muscarine M3 receptors, respiratory system disorders; side effect reduction, use as inhalants
10/09/2003US20030191291 Synthetic erythropoiesis stimulating proteins
10/09/2003US20030191285 Novel g protein-coupled receptor proteins and dnas thereof
10/09/2003US20030191176 Stable hydrate of a muscarinic receptor antagonist
10/09/2003US20030191175 Indole sPLA2 inhibitors
10/09/2003US20030191170 Central nervous system disorders; antiallergens; respiratory system disorders
10/09/2003US20030191167 Autoimmune disease, antiarthritic agents, antiallergens, anticancer agents
10/09/2003US20030191158 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
10/09/2003US20030191148 Macrolides
10/09/2003US20030191118 Inhibitors of alpha4 mediated cell adhesion
10/09/2003US20030191103 Hormone replacement therapy
10/09/2003US20030191097 Hormone replacement therapy
10/09/2003US20030191092 MMP inhibitors
10/09/2003US20030191079 Methods for treating and preventing infectious disease
10/09/2003US20030191074 Antibody therapy; immobilization
10/09/2003US20030191065 Insulin-like growth factor; genetic engineering; central nervous system disorders
10/09/2003US20030191057 Cardiovascular disorders; antiinflammatory agents
10/09/2003US20030190733 Desaturase genes and uses thereof
10/09/2003US20030190685 Bind to Tumor Necrosis Factor(TNF)-Related Apoptosis Inducing Ligand (TRAIL) receptors ; used in the prevention and treatment of cancers and other proliferative disorders
10/09/2003US20030190651 Preventing, ameliorating, correcting dysfunctions or diseases such as cancer, peripheral and central nervous system diseases, and chronic obstructive pulmonary disease
10/09/2003US20030190642 Thymus expressed human cytochrome p450(p450tec)
10/09/2003US20030190613 Polynucleotide encoding an activated human T-lymphocyte-derived protein related to ubiquitin conjugating enzyme
10/09/2003US20030190607 Polymorphisms in human pyruvate dehydrogenase E1 beta (PDH E1 beta) gene; for analysing allelic variation; bioinformatic applications
10/09/2003US20030190372 Cough depressant composition containing iron for angiotensin-converting enzyme inhibitor inducing cough
10/09/2003US20030190360 Chronotherapeutic pharmaceutical formulation comprising core containing active agent and delayed release compression coating comprising a natural or synthetic gum applied onto surface of core
10/09/2003US20030190314 Administering spray dried plasma for modulating immunoglobulin levels; vaccines; for weight gain; autoimmune disorders
10/09/2003US20030190303 For treating allergic disorders characterized by a local immune response including inflammatory skin reactions, asthma, and arthritis
10/09/2003US20030190289 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
10/09/2003CA2480888A1 New aryl imidazoles and related compounds as c5a receptor modulators
10/09/2003CA2480857A1 Improvements in pharmaceutical compositions
10/09/2003CA2480679A1 (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
1 ... 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 ... 878